NAPLEX • PERSON-CENTERED ASSESSMENT AND TREATMENT PLANNING

Medication Reconciliation

Ensuring accurate, complete medication lists at every care transition to prevent adverse drug events.

Historical Context & Motivation

The concept of medication reconciliation arose from a growing recognition that medication errors at transitions of care—admission, transfer, and discharge—constitute one of the most significant and preventable threats to patient safety. Studies in the late 1990s and early 2000s revealed that up to 67% of hospitalized patients had at least one unintended medication discrepancy at admission, many of which carried the potential to cause serious harm. These findings catalyzed a formal, systematic process designed to create a single, verified list of every medication a patient is taking and to compare that list against provider orders at each transition point. Medication reconciliation has since evolved from a loosely defined best practice into a national patient safety priority with regulatory mandates, standardized processes, and interprofessional accountability frameworks.

1999
IOM Report — To Err Is Human
The Institute of Medicine's landmark report estimated that up to 98,000 Americans died annually from preventable medical errors, including medication errors. This galvanized national attention toward systemic safety improvements.
2005
Joint Commission NPSG #8
The Joint Commission introduced National Patient Safety Goal (NPSG) #8, mandating that accredited organizations implement a process for accurately and completely reconciling medications across the continuum of care.
2006
IHI High 5s Project
The Institute for Healthcare Improvement launched the High 5s initiative, identifying medication reconciliation as one of five global patient safety challenges. International standardization efforts began.
2011
Joint Commission NPSG 03.06.01
The original NPSG #8 was updated and renumbered as NPSG 03.06.01, refining the requirement to maintain and communicate an accurate medication list at every transition of care.
2017–Present
EHR Integration & Pharmacist-Led Models
Electronic health record systems began integrating reconciliation modules, and robust evidence demonstrated that pharmacist-led medication reconciliation significantly reduces discrepancies, adverse drug events, and 30-day readmissions.

Despite decades of awareness, unintended medication discrepancies remain alarmingly common. Research consistently shows that 30–70% of patients experience at least one discrepancy at hospital admission, and approximately one-third of these discrepancies have the potential to cause moderate to severe harm. The central question driving medication reconciliation is straightforward yet profoundly important: How do we ensure that every patient's medication regimen is accurate, intentional, and safely communicated across every point of care transition?

Core Principles & Definitions

Medication reconciliation is fundamentally a three-step comparative process. The clinician first compiles the Best Possible Medication History (BPMH)—a comprehensive, verified list of all medications the patient is actually taking, including prescription drugs, over-the-counter products, herbals, supplements, and recreational substances. Next, this list is compared against the current set of medication orders (at admission, transfer, or discharge). Finally, any discrepancies are identified, classified as intentional or unintentional, and resolved through collaboration with the prescriber and the patient. This process must occur at every transition of care—a term encompassing admission, intra-facility transfer, and discharge to home, long-term care, or another facility.

1

Verification

Compile a thorough, accurate BPMH using at least two reliable sources (patient interview, pharmacy records, pill bottles, caregiver confirmation). Verify drug name, dose, route, and frequency.
2

Clarification

Ensure each medication and dose is appropriate for the patient's current clinical status. Resolve ambiguities in drug names, strengths, or formulations before proceeding.
3

Reconciliation

Compare the BPMH against current orders. Identify and classify every discrepancy—omission, commission, dose change, or therapeutic substitution—as intentional or unintentional. Resolve and document each.
4

Communication

Transmit the reconciled medication list to the next provider and the patient. At discharge, provide clear written and verbal counseling on all changes to the home regimen.
5

Documentation

Record the reconciled list within the electronic health record so it is accessible at the next transition. Document the rationale for intentional changes to prevent future re-discrepancies.
KEY TAKEAWAY
Think of medication reconciliation like an airport security checkpoint for medications. Every time a patient moves from one care setting to another (like changing gates), each medication must be scanned, verified, and cleared before it can continue the journey. Just as an unscreened bag could be dangerous, an unreconciled medication—whether accidentally omitted, duplicated, or dosed incorrectly—poses a preventable safety risk.

The Medication Reconciliation Process — Visual Overview

The upper row illustrates the four-step workflow (collect, clarify, compare, resolve). The middle row shows the three principal care transitions—admission, transfer, and discharge—at which reconciliation is required. The lower panel lists the key sources used to construct a Best Possible Medication History.

As the diagram illustrates, the medication reconciliation process follows a linear yet iterative pathway. The pharmacist or other qualified clinician begins by collecting a Best Possible Medication History using multiple, corroborating sources—a patient interview alone is insufficient because patients frequently omit OTC products, misstate doses, or confuse generic and brand names. Pharmacy dispensing records, medication administration records from referring facilities, physical inspection of pill bottles, and caregiver input each provide complementary information. Once the BPMH is assembled, each medication is clarified for accuracy—correct drug name, strength, formulation, route, and frequency. This clarified list is then compared against the provider's active orders, and every discrepancy is flagged. A discrepancy is unintentional unless the prescriber explicitly documents the change as a deliberate clinical decision. The final step—documentation and communication—closes the loop by transmitting the reconciled list forward to the patient and the next care team.

How Medication Reconciliation Works in Practice

Discrepancy Classification Framework

When the BPMH is compared against active medication orders, clinicians encounter five principal categories of discrepancies. Understanding this taxonomy is critical because each type carries a distinct risk profile and requires a different resolution pathway. An omission occurs when a home medication is absent from the admission orders without documented justification—this is the single most common discrepancy type, accounting for approximately 40–50% of all unintended discrepancies. A commission (or addition) is the ordering of a medication the patient was not previously taking, without a clear clinical indication documented in the chart. A dose, frequency, or route discrepancy occurs when the ordered parameters differ from the home regimen without explanation. A therapeutic duplication arises when two agents from the same pharmacologic class are prescribed concurrently without clear rationale. Finally, a therapeutic substitution may be intentional (formulary-driven) or unintentional, and must be verified with the prescriber.

Classification of medication discrepancies encountered during reconciliation
Discrepancy TypeDefinitionExampleApproximate Prevalence
OmissionHome medication not ordered at transitionLevothyroxine 75 mcg daily not on admission orders40–50%
CommissionNew medication ordered without indicationPantoprazole 40 mg ordered for patient with no GI indication10–15%
Dose / Route / FrequencyOrdered parameter differs from verified home regimenMetoprolol tartrate 25 mg BID ordered; home dose is 50 mg BID20–30%
Therapeutic DuplicationTwo agents from same class without justificationHome lisinopril continued while enalapril ordered inpatient5–10%
Therapeutic SubstitutionDifferent drug in same class substituted (may be formulary-driven)Home omeprazole switched to pantoprazole per hospital formulary5–15%

The Pharmacist's Role in the Reconciliation Process

Pharmacists are uniquely positioned to lead medication reconciliation because of their comprehensive drug knowledge, access to dispensing records, and training in patient communication regarding medication use. The pharmacist conducts a structured interview that probes beyond prescription medications to include OTC agents, herbal products, vitamins, eye drops, inhalers, topical preparations, and any medications recently discontinued. The interview should also assess adherence—a patient who reports 'sometimes forgetting' their amlodipine may not be a true candidate for continuation of the same dose. Clinical judgment is required at every step: the pharmacist must determine whether a discrepancy is clinically significant, communicate recommendations clearly to prescribers, and ensure the patient understands any changes at discharge. Evidence from randomized controlled trials demonstrates that pharmacist-led reconciliation reduces the rate of unintended discrepancies by 50–80% compared with physician-only or nursing-only processes.

📋 NAPLEX Relevance
The NAPLEX frequently tests your ability to identify unintentional discrepancies in a patient scenario, determine appropriate resolution (contact prescriber, recommend continuation, recommend discontinuation), and prioritize which discrepancies require immediate action based on clinical severity. Know the distinction between intentional and unintentional discrepancies—the former are documented clinical decisions; the latter are errors requiring correction.

Detailed Breakdown — Types, Severity, and Risk Factors

Not all medication discrepancies carry equal clinical significance. A systematic approach to severity classification helps pharmacists prioritize interventions, allocate limited time effectively, and communicate risk to prescribers with appropriate urgency. The following visual framework stratifies discrepancies by their potential for patient harm, guiding the urgency and type of intervention required.

The severity pyramid stratifies discrepancies by harm potential: high-severity discrepancies involving high-alert medications (anticoagulants, insulin, opioids) demand immediate resolution, while low-severity discrepancies may be addressed within a standard workflow. The four risk-factor categories below the pyramid identify the characteristics that increase the likelihood of discrepancies occurring.

High-Alert Medications Requiring Priority Reconciliation

The Institute for Safe Medication Practices (ISMP) maintains a list of high-alert medications that bear a heightened risk of causing significant patient harm when used in error. During medication reconciliation, these agents should receive the highest priority. The mnemonic A PINCH is commonly used to remember the high-risk categories: Anti-infectives, Potassium and other electrolytes, Insulin, Narcotics (opioids), Chemotherapeutic agents, and Heparin and anticoagulants. Discrepancies involving these drug classes should be flagged for immediate prescriber notification and resolution.

  • Polypharmacy (≥5 chronic medications) is the single strongest predictor of reconciliation discrepancies; every additional medication increases discrepancy risk by approximately 5–10%.
  • Emergency admissions carry higher discrepancy rates than elective admissions because the BPMH is often collected under time pressure and the patient may be unable to provide a reliable history.
  • Elderly patients (≥65 years) frequently manage multiple chronic conditions, use multiple pharmacies, and may have cognitive barriers to providing accurate medication histories.
  • Transitions involving different EHR systems create information gaps when medication lists from separate platforms cannot be electronically cross-referenced.

Worked Example — Admission Reconciliation Case

The following case demonstrates how a pharmacist performs medication reconciliation at hospital admission. Pay close attention to the systematic comparison of the BPMH against admission orders and the clinical reasoning behind each discrepancy resolution.

🏥 Patient Scenario
Mrs. R.J. is a 72-year-old woman admitted to the medical floor from the emergency department with community-acquired pneumonia. She has a history of hypertension, type 2 diabetes, hypothyroidism, atrial fibrillation, and GERD. Her daughter brought in a bag of pill bottles, and the community pharmacy faxed a dispensing history.
Admission Medication Reconciliation for Mrs. R.J.
1
Step 1 — Compile the Best Possible Medication HistoryThe pharmacist interviews Mrs. R.J., cross-references her pill bottles, and reviews the community pharmacy fax. Three sources are triangulated. The verified BPMH includes: (1) Lisinopril 20 mg PO daily, (2) Metformin 1000 mg PO BID, (3) Levothyroxine 88 mcg PO daily, (4) Warfarin 5 mg PO daily, (5) Omeprazole 20 mg PO daily, (6) Calcium carbonate 600 mg PO BID (OTC), and (7) Aspirin 81 mg PO daily (OTC). Mrs. R.J. reports taking all medications as prescribed.
BPMH: 7 medications verified from 3 sources
2
Step 2 — Review Admission OrdersThe admitting physician wrote the following orders: (1) Lisinopril 10 mg PO daily, (2) Metformin 1000 mg PO BID, (3) Warfarin 5 mg PO daily, (4) Pantoprazole 40 mg IV BID, and (5) Levofloxacin 750 mg IV daily (new—for pneumonia). No orders for levothyroxine, calcium carbonate, or aspirin.
5 admission orders identified; 3 home medications absent
3
Step 3 — Identify and Classify DiscrepanciesComparing the BPMH against admission orders reveals five discrepancies: (A) Lisinopril dose changed from 20 mg to 10 mg—dose discrepancy. (B) Levothyroxine 88 mcg omitted—omission. (C) Aspirin 81 mg omitted—omission (high priority given concurrent warfarin for atrial fibrillation). (D) Calcium carbonate 600 mg BID omitted—omission. (E) Omeprazole 20 mg PO daily replaced with pantoprazole 40 mg IV BID—therapeutic substitution with dose/route change.
5 discrepancies: 3 omissions, 1 dose change, 1 therapeutic substitution
4
Step 4 — Assess Clinical Significance and PrioritizeThe pharmacist triages by severity. Levothyroxine omission is high priority—abrupt discontinuation can cause myxedema and altered mental status, especially in an acutely ill elderly patient. Aspirin omission in a patient on warfarin for atrial fibrillation may or may not be intentional (dual therapy is not universally recommended). The lisinopril dose reduction may be intentional if the patient is hypotensive on presentation. Calcium omission is low severity. Pantoprazole substitution at a higher dose and IV route warrants clarification.
Highest priority: Levothyroxine omission → contact prescriber immediately
5
Step 5 — Resolve Discrepancies and DocumentThe pharmacist contacts the admitting physician. Outcomes: (A) Lisinopril reduced to 10 mg intentionally due to admission BP of 98/62—documented as intentional, will reassess. (B) Levothyroxine 88 mcg daily added to orders—unintentional omission corrected. (C) Aspirin intentionally held per physician due to concurrent warfarin and risk of GI bleeding with pneumonia—documented. (D) Calcium carbonate added back to orders—unintentional omission corrected, with note to separate administration from levothyroxine by 4 hours. (E) Pantoprazole 40 mg IV BID converted to pantoprazole 40 mg PO daily (patient can take PO)—formulary substitution accepted but dose and route corrected. All resolutions documented in the EHR reconciliation module.
All 5 discrepancies resolved: 2 unintentional omissions corrected, 2 intentional changes documented, 1 substitution modified

Strengths, Barriers, and Interprofessional Considerations

Medication reconciliation has demonstrated robust clinical value across diverse healthcare settings, but implementation remains challenging. Understanding both the strengths and barriers of reconciliation programs is essential for pharmacy professionals who will design, execute, and advocate for these systems.

Comparative analysis of medication reconciliation strengths versus common barriers to effective implementation
Strengths / BenefitsBarriers / Limitations
Reduces unintended medication discrepancies by 50–80% when pharmacist-ledTime-intensive process; average 20–30 minutes per patient for complex regimens
Decreases adverse drug events (ADEs) at transitions of careLack of standardized processes across institutions; wide variability in quality
Lowers 30-day hospital readmission rates, particularly for high-risk patientsIncomplete or inaccessible medication records, especially across EHR systems
Improves patient understanding of their medication regimen at dischargePatient factors: unreliable self-reporting, cognitive impairment, language barriers
Meets Joint Commission NPSG 03.06.01 requirements; supports accreditationCan become a 'checkbox' exercise if not supported by clinical judgment and workflow design
Strengthens interprofessional collaboration between pharmacists, physicians, and nursesRole ambiguity: unclear ownership of the reconciliation process in some settings
KEY TAKEAWAY
Medication reconciliation is only as strong as its weakest information source. Like a chain in engineering, a single unreliable link—whether an incomplete pharmacy record, a patient who cannot communicate, or an EHR that fails to transfer data—can undermine the entire process. The pharmacist's role is to identify and reinforce each link by using multiple corroborating sources and applying clinical judgment to resolve ambiguities. The most effective reconciliation programs combine technology (EHR reconciliation modules, state prescription drug monitoring programs) with human expertise (pharmacist-conducted interviews, interprofessional communication) and patient engagement (teach-back at discharge, updated medication cards).

Connection to Advanced Practice & Emerging Models

While the foundational medication reconciliation process is well established, advanced practice models and emerging technologies are expanding its scope and effectiveness. Understanding where basic reconciliation ends and advanced, person-centered models begin helps pharmacy students appreciate the trajectory of the profession and the opportunities for impactful clinical practice.

Standard medication reconciliation compared with advanced, person-centered reconciliation models
FeatureStandard ReconciliationAdvanced / Person-Centered Model
ScopeCompares medication lists at transitionsIntegrates comprehensive medication review, deprescribing, and adherence assessment
PersonnelAny trained clinician; often nurses or pharmacy techniciansPharmacist-led with technician support; includes prescriber collaboration
TechnologyEHR medication list moduleInteroperable health information exchanges (HIEs), PDMP integration, AI-assisted discrepancy detection
Patient EngagementProvides discharge medication listTeach-back method, patient-held medication card, follow-up phone calls within 48–72 hours
Outcome FocusDiscrepancy identification and correctionReduced readmissions, improved adherence, medication optimization, patient-reported outcomes
Regulatory AlignmentJoint Commission NPSG 03.06.01CMS Comprehensive Medication Management, ASHP/APhA guidelines, value-based payment incentives

Looking forward, the field is moving toward continuous reconciliation rather than episodic, transition-based reconciliation. Health information exchanges (HIEs) and prescription drug monitoring programs (PDMPs) are beginning to provide real-time, cross-platform medication data that can alert clinicians to discrepancies before they become errors. Artificial intelligence algorithms are being developed to flag high-risk discrepancies automatically upon order entry, reducing the cognitive burden on pharmacists while maintaining safety. Telepharmacy models extend reconciliation services to rural and underserved populations that lack on-site clinical pharmacists. As value-based care models increasingly tie reimbursement to 30-day readmission rates and medication safety metrics, pharmacist-led reconciliation becomes not only a clinical imperative but also a financial one for health systems.

Practice Problems

PROBLEM 1CONCEPTUAL
A nurse compiles a patient's medication list from the electronic health record alone and enters it into the admission reconciliation module. Why is this approach insufficient for constructing a Best Possible Medication History (BPMH), and what additional sources should be consulted?
PROBLEM 2BASIC CALCULATION
A study of 200 hospitalized patients finds that 130 had at least one medication discrepancy at admission. Of the total 340 discrepancies identified, 153 were omissions, 68 were dose/frequency/route errors, 51 were therapeutic substitutions, 34 were commissions, and 34 were therapeutic duplications. Calculate the discrepancy rate per patient and the percentage of discrepancies classified as omissions.
PROBLEM 3INTERMEDIATE
Mr. T.K. is a 68-year-old man being discharged after a 5-day hospitalization for heart failure exacerbation. His home medications included carvedilol 25 mg PO BID, lisinopril 40 mg PO daily, furosemide 40 mg PO daily, and atorvastatin 40 mg PO daily. At discharge, his orders list: carvedilol 12.5 mg PO BID, lisinopril 20 mg PO daily, furosemide 80 mg PO BID, spironolactone 25 mg PO daily (new), and atorvastatin 40 mg PO daily. Identify each discrepancy, classify it, and determine whether it is likely intentional or unintentional.
PROBLEM 4APPLIED
You are a pharmacist designing a medication reconciliation improvement program for a 300-bed community hospital. Current data show a 62% discrepancy rate at admission, a mean of 2.1 discrepancies per patient, and only 35% of reconciliations are completed within 24 hours of admission. Describe the key components of an intervention to improve these metrics, including staffing model, technology utilization, workflow changes, and outcome measures you would track.
PROBLEM 5CRITICAL THINKING
A hospitalized patient with limited English proficiency and no accompanying family member is admitted through the emergency department at 2 a.m. She has no pill bottles, no pharmacy records are immediately available, and the EHR medication list was last updated 8 months ago. Critically analyze the ethical and clinical tensions in this scenario. How should the pharmacist approach reconciliation, what interim safety measures should be employed, and when is it appropriate to use a provisional medication list?

Medication Reconciliation — Key Concepts Review

Medication reconciliation is a systematic, patient-centered process that compares a patient's verified Best Possible Medication History (BPMH) against current medication orders at every transition of care—including admission, transfer, and discharge. The process follows four core steps: verification (compiling and confirming the BPMH from multiple sources), clarification (ensuring accuracy of drug name, dose, route, and frequency), reconciliation (identifying and resolving discrepancies as intentional or unintentional), and communication (transmitting the reconciled list to patients and the next care team). The five principal discrepancy types are omissions (most common at 40–50%), commissions, dose/route/frequency errors, therapeutic duplications, and therapeutic substitutions.

Pharmacists are the ideal leaders of reconciliation due to their medication expertise, access to dispensing records, and patient communication training. High-alert medications (remembered by the A PINCH mnemonic: anti-infectives, potassium, insulin, narcotics, chemotherapy, heparin/anticoagulants) require priority reconciliation. Key risk factors for discrepancies include polypharmacy, advanced age, emergency admissions, non-interoperable EHR systems, and cognitive or language barriers. The Joint Commission NPSG 03.06.01 mandates reconciliation at all care transitions, and emerging models are advancing toward continuous, technology-enabled reconciliation integrated with comprehensive medication management, deprescribing, and person-centered outcome measurement.

Varsity Tutors • NAPLEX • Medication Reconciliation